Sugam Submission: The Complete 2026 Guide to CDSCO’s Online Drug Application Portal

If you are a pharmaceutical company, a biotech sponsor, a clinical research organisation, or a medical device manufacturer planning to register or conduct clinical activities in India, there is one digital system you need to understand before anything else: the SUGAM portal.

India is the world’s third-largest pharmaceutical industry by volume, with a rapidly maturing regulatory infrastructure under the Central Drugs Standard Control Organisation (CDSCO). All drug registrations, clinical trial services approvals, import licences, and medical device registrations now flow through a single electronic system – SUGAM – and getting your submission right on that portal is the difference between a smooth approval timeline and months of avoidable delay.

This guide covers everything sponsors need to know about SUGAM submission in 2026: what the portal is, what it handles, how to navigate it, what documentation is required, and the most common mistakes that send applications back.

Quick Answer

The SUGAM portal is CDSCO’s official online platform for submitting, tracking, and managing regulatory applications in India – including new drug registrations, clinical trial services permissions, medical device approvals, and import licences. Applications must be submitted in CTD format (eCTD recommended for new drugs), with India-specific Module 1 documentation tailored to CDSCO requirements. The NDCT Amendment Rules 2026 update several requirements relevant to clinical trial sponsors.

What Is the SUGAM Portal?

SUGAM – an acronym for Sugam (easy) – is CDSCO’s integrated e-governance system for electronic submission and tracking of regulatory applications. Before SUGAM, applicants physically submitted paper dossiers to CDSCO offices. The transition to an electronic, centralised system has significantly improved transparency, tracking, and communication between sponsors and regulators.

The portal handles:

• New drug applications (NDAs) for drugs not previously approved in India
• Import registration certificates for foreign drugs
• Clinical trial services applications – CT-01, CT-04, and CT-06 forms under NDCT Rules 2019
• Abbreviated New Drug Applications (ANDAs) for generic drugs
• Medical device registration (Classes A, B, C, and D)
• Cosmetics manufacturing and import approvals
• Licence renewals and variation applications
• Export certificates and No Objection Certificates (NOCs)

For any company needing a licence or approval from CDSCO, SUGAM is where the regulatory journey in India begins and where it is tracked throughout.

The Regulatory Framework: NDCT Rules 2019 and the 2026 Amendment

The New Drugs and Clinical Trials (NDCT) Rules, 2019 – issued under India’s Drugs and Cosmetics Act, 1940 – is the foundational framework governing clinical trial permissions, new drug approvals, Ethics Committee registrations, and bioavailability/bioequivalence (BA/BE) studies in India.

In January 2026, the Ministry of Health and Family Welfare notified the New Drugs and Clinical Trials (Amendment) Rules, 2026 (G.S.R. 46(E), dated 20 January 2026). Sponsors running clinical trial services in India should review this amendment carefully – it introduces updated documentation requirements and procedural clarifications that affect SUGAM submissions.

The DCGI (Drugs Controller General of India), who heads CDSCO, is the Central Licensing Authority under the NDCT Rules and the officer who grants or refuses clinical trial permission and new drug approval. All correspondence with CDSCO flows through the SUGAM portal.

SUGAM Application Types and Timelines

Key Application Types, Forms, and Review Timelines

Step-by-Step Guide to SUGAM Submission

Step 1: Register on the SUGAM Portal

Every sponsor, manufacturer, or authorised agent must create an account on the SUGAM portal (sugam.pharma.gov.in) before any application can be submitted. The registration process requires:

• A valid business email address and Indian mobile number for OTP verification
• Company registration documents (Certificate of Incorporation or equivalent)
• For foreign companies: appointment letter for the Authorised Indian Agent, who must hold a valid wholesale drug licence in India
• Digital Signature Certificate (DSC) for authorised signatories

Account verification typically takes 3 to 5 working days after document submission.

Step 2: Prepare Your CTD Dossier

All new drug applications and clinical trial services applications submitted through SUGAM must be organised in Common Technical Document (CTD) format. For new drug applications, eCTD format is recommended and increasingly expected. The five CTD modules are:

• Module 1 – India-specific administrative and regional information (this is where most SUGAM-specific errors occur)
• Module 2 – Summaries and overviews (Quality Overall Summary, Non-Clinical Overview, Clinical Overview, Clinical Summary)
• Module 3 – Quality / Chemistry, Manufacturing, and Controls (CMC)
• Module 4 – Non-clinical study reports
• Module 5 – Clinical study reports (including all clinical trial data management outputs)

India-specific Module 1 is the section most frequently incomplete in SUGAM submissions. Key required items include:

• Covering letter and Form 44 (or the applicable form for the application type)
• Proof of approval in the country of origin (for imported drugs), with translations if not in English
• GMP certificates for all manufacturing sites, valid at the time of submission
• Site master file or abbreviated site master file for manufacturing sites
• Prescribing information in the format approved in the reference country
• Declaration by the applicant regarding bioequivalence and safety

Step 3: Address Local Clinical Data Requirements

CDSCO may require India-specific clinical bridging data for new drugs not previously approved in the major ICH reference countries (US, EU, Japan, UK, Canada, Australia). The requirement is evaluated on a product-by-product basis and may involve:

• Clinical trial services – Phase III bridging studies in Indian patients
• Phase I pharmacokinetic studies in Indian subjects
• Post-marketing safety data in Indian patients for drugs already approved elsewhere

Sponsors should seek expert regulatory advice early – ideally at pre-SUGAM submission consultation, if available to determine whether local clinical data will be required for their specific product.

Step 4: Submit Through SUGAM and Pay Fees

Once the dossier is prepared and the account is verified, the application is uploaded through SUGAM and the applicable fee is paid electronically. CDSCO fee schedules are published on the SUGAM portal and vary by application type, drug category, and whether the application is from a domestic or foreign manufacturer.

After submission, SUGAM provides a reference number that enables real-time tracking of the application status, communication of CDSCO queries, and management of the entire review lifecycle digitally.

Step 5: Respond to CDSCO Queries

CDSCO reviewers issue written queries through the SUGAM portal during the review. These must be responded to within the timeframe specified in the query notification. Each query response must be uploaded to SUGAM as a structured response document.

The quality of query responses is a critical determinant of approval timeline. A precise, complete, and well-structured response drafted by experienced regulatory medical writing specialists can resolve a query in one cycle. A vague or incomplete response extends the review.

Common SUGAM Submission Errors

Incorrect application form selection: CT-01 (new clinical trial), CT-04 (import of investigational product for trial), and CT-06 (BA/BE study) serve different purposes. Using the wrong form is a frequent and easily avoidable error.

Incomplete Module 1 India documentation: Missing GMP certificates, absent proof of origin country approval, or outdated prescribing information are the most frequently cited completeness deficiencies in CDSCO review feedback.

Absent or insufficient local bridging data: Where CDSCO requires local clinical data, submitting without it – or with inadequate data – results in rejection or a request for a bridging study that adds months to the timeline.

Dossier formatting non-compliance: Submissions not organised in CTD format, or with files submitted in non-PDF formats, or without the structured CTD table of contents, generate immediate technical rejection.

Expired GMP certificates at time of review: GMP certificates that were valid at submission may expire during the review period. Sponsors should track certificate expiry dates and upload renewals proactively through SUGAM.

How SUGAM Fits Into a Global Regulatory Strategy

For sponsors conducting multi-country clinical trial services or pursuing simultaneous marketing authorisations, SUGAM submission in India must be planned alongside submissions to the FDA, EMA, MHRA, TGA, and other authorities.

India is an increasingly significant target market and a high-value clinical trial location – particularly for rare diseases, oncology, infectious disease, and CNS conditions where India offers large patient populations, lower study costs, and experienced site networks. Experienced clinical research organisations operating in India combine SUGAM expertise with global CTD dossier preparation capability to ensure India timelines align with global submission plans.

The global regulatory medical writing approach – building Module 2 summaries and overviews that work across FDA, EMA, and CDSCO, with authority-specific Module 1 adaptations – is the most efficient path for sponsors pursuing simultaneous global approvals.